Michael T Tetzlaff

86PUBLICATIONS
617CO-AUTHORS
Tumour immunologyMolecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (86)

|Sep 02, 2026
Functionally active lymphoid aggregates correlate with improved prognosis in brain metastases.

|Jun 26, 2026
Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma.

|Jun 26, 2026
The Imipridone ONC206 Inhibits Tumor Growth and Improves Survival in Patient-Derived Xenograft Models of Uveal Melanoma.

|May 18, 2026
FGFR1 but not S6K1/2 drives intrinsic BRAF inhibitor resistance in melanoma.

|Apr 28, 2026
Rapid activation of ARF6 after RAF inhibition augments BRAFV600E and promotes therapy resistance.

|Apr 21, 2026
Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study.

Pageof 15

Frequent Collaborators

19 joint publications

Jennifer Wargo

18 joint publications

Hussein Tawbi

18 joint publications

Alexander Lazar

17 joint publications

Sapna Patel